Phase II Study of Pembrolizumab and Ablative Radiotherapy With or Without Olaparib in Metastatic Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancers : Initial Test Cohorts of a Platform Trial to Sequentially Investigate Immunotherapy Combinations for the Augmentation of Immune Responses
Latest Information Update: 09 Oct 2023
At a glance
- Drugs Olaparib (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 19 Oct 2022 Planned number of patients changed from 56 to 34.
- 21 Apr 2021 Status changed from not yet recruiting to recruiting.
- 01 Mar 2021 Planned initiation date changed from 1 Jan 2021 to 1 Jun 2021.